Bioscience, Medicinal Chemistry, Pharmacology and Protein Science Departments, Sygnature Discovery Ltd, BioCity, Pennyfoot Street, Nottingham NG1 1GR, UK.
Bioscience, Medicinal Chemistry, Pharmacology and Protein Science Departments, Sygnature Discovery Ltd, BioCity, Pennyfoot Street, Nottingham NG1 1GR, UK.
SLAS Discov. 2024 Jan;29(1):1-22. doi: 10.1016/j.slasd.2023.08.007. Epub 2023 Aug 23.
G-protein-coupled receptors (GPCRs) are the largest and most versatile cell surface receptor family with a broad repertoire of ligands and functions. We've learned an enormous amount about discovering drugs of this receptor class since the first GPCR was cloned and expressed in 1986, such that it's now well-recognized that GPCRs are the most successful target class for approved drugs. Here we take the reader through a GPCR drug discovery journey from target to the clinic, highlighting the key learnings, best practices, challenges, trends and insights on discovering drugs that ultimately modulate GPCR function therapeutically in patients. The future of GPCR drug discovery is inspiring, with more desirable drug mechanisms and new technologies enabling the delivery of better and more successful drugs.
G 蛋白偶联受体(GPCRs)是最大和最多样化的细胞表面受体家族,具有广泛的配体和功能。自 1986 年首次克隆和表达第一个 GPCR 以来,我们已经了解到很多关于发现此类受体的药物,现在已经清楚地认识到 GPCR 是批准药物中最成功的靶标类别。在这里,我们带领读者了解从靶标到临床的 GPCR 药物发现之旅,重点介绍发现最终在患者中调节 GPCR 功能的治疗药物的关键经验、最佳实践、挑战、趋势和见解。GPCR 药物发现的未来令人鼓舞,更理想的药物机制和新技术使更好、更成功的药物得以交付。